HCAR2 and metabolic syndrome: Thus, although HCAR2 is no longer a valid drug target in dyslipidemia and likely not in diabetes either, the many HCAR2 ligands could potentially become useful as anti-inflammatory agents in the treatment of neuroinflammation and e.g. psoriasis42,43.